Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7W9MT)

Drug Name

KF 17837S Drug Info

Synonyms

152881-18-0; 8-(3,4-Dimethoxyphenyl)-7-methyl-1,3-dipropyl-1H-purine-2,6(3H,7H)-dione; 8-(3,4-dimethoxyphenyl)-7-methyl-1,3-dipropylpurine-2,6-dione; 1,3-Dipropyl-7-methyl-8-(3,4-dimethoxystyryl)xanthine; AC1L3X7D; GTPL428; CTK8C1262; DTXSID30165151; ZINC5114737; 7673AA; ANW-66125; AKOS016004661; 8-(3,4-Dimethoxyphenyl)-3,7-dihydro-7-methyl-1,3-dipropyl-1H-purine-2,6-dione; AJ-53127; AX8236469; L001123; 1H-Purine-2,6-dione, 8-(3,4-dimethoxyphenyl)-3,7-dihydro-7-methyl-1,3-dipropyl-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 123739
CAS Number: CAS 152881-18-0
TTD Drug ID: DM7W9MT

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adenosine A2b receptor (ADORA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[3]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[3]
A295	DM55GO2	Aggressive cancer	2A00-2F9Z	IND submitted	[4]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[5]
YT-146	DM3YVKQ	Hypertension	BA00-BA04	Phase 2	[6]
AB928	DMDOXMN	Metastatic colorectal cancer	2B91	Phase 1/2	[7]
KF-17837	DMQ6DLZ	Parkinson disease	8A00.0	Phase 1	[8]
Xanthine	DMFBOQ7	Apnea	MD11.0	Phase 1	[9]
CVT-6883	DMY84TW	Asthma	CA23	Phase 1	[10]
PBF-1129	DMOPGXM	Non-small-cell lung cancer	2C25.Y	Phase 1	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A2b receptor (ADORA2B)	TTNE7KG	AA2BR_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 428).
2	Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Br J Pharmacol. 1997 Jun;121(3):353-60.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Clinical pipeline report, company report or official report of Klus Pharma
5	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
6	Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
9	Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
10	GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.